GAPDH and breast cancer: Taken together, our results demonstrated that DC-5163, a novel inhibitor targeting GAPDH, suppressed aerobic glycolysis and reduced the energy supply of breast cancer cells, thereby leading to the inhibition of proliferation and increase of apoptosis.